Washington – The morning-after contraception pill known as Plan B reached a regulatory milepost Tuesday with still no word from the Food and Drug Administration whether it will be sold without a prescription.
Tuesday marked the end of 60 days of public comment sought by the agency after it delayed a final decision whether to approve over-the-counter sales despite substantial agreement among agency scientists that the pill was safe and effective. An FDA spokeswoman said that as of Monday, the agency had received 2,268 comments, but she said they had not been analyzed yet.
“We will review the public comments as soon as practicable and, taking those comments into account, decide how to proceed,” spokeswoman Julie Zawisza said in an e-mail.
Proponents of Plan B used the occasion to urge the FDA to rule on over-the-counter sales.
